Advances in Management of Pediatric Brain Tumors, Volume 167 encapsulates the latest developments in the field for various types of pediatric brain tumors. By examining these survival gaps, the volume offers insights into strategies for improving outcomes and bridging the gap in care on a global scale. Chapters in this new release include Pediatric-type diffuse low grade gliomak, Pediatric-type diffuse high grade glioma/Diffuse Midline glioma, Ependymoma, Choroid plexus tumors, Embryonal tumors/medulloblastoma, Craniopharyngioma and other sellar-region tumors, and much more. Other sections cover Germ cell tumors, Immunotherapy for pediatric brain tumors, Emerging interventional treatments in the management of pediatric brain tumors, and Management of pediatric brain tumors in low-middle income countries. Provides the most up-to-date diagnostic criteria for pediatric brain tumors, aligned with the latest CNS WHO classification - Explores the latest breakthroughs in targeted therapies, offering new hope and precision in the treatment of pediatric brain tumors - Includes insights on the unique challenges and innovative approaches to diagnosing and managing pediatric brain tumors in LMICs, aiming to bridge the gap in care and improve global outcomes Presents comprehensive insights and expert analyses on how CNS WHO classification changes have influenced the management of pediatric brain tumors Pediatric brain tumors have become the leading cause of cancer-related death in children. Significant advances in diagnosis and management have been made in recent years, and this volume encapsulates the latest developments in the field for various types of pediatric brain tumors. Additionally, this book addresses the stark disparities in outcomes for pediatric brain tumors in low- and middle-income countries (LMICs). By examining these survival gaps, the volume offers insights into strategies for improving outcomes and bridging the gap in care on a global scale. Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018). David D. Limbrick Jr., MD, PhD is Professor and Chair of Neurosurgery at Virginia Commonwealth University School of Medicine and VCU Health. He holds the James W. and Francis G. McGlothlin Chair in Neurosurgery. His clinical focus is on pediatric brain tumors and innovative surgical methods for brain tumors as they occur across the lifespan. Dr. Limbrick is internationally regarded for his expertise in neuro-endoscopic treatment of intracranial disease and for treating complex disorders of the craniovertebral junction, including the Chiari malformations. He has received the Public Service Citation from the American Association of Neurological Surgeons and Congress of Neurological Surgeons for international neurosurgical relief